BioStock: Janssen CAR T deal supports Elicera’s vision

The 245 million USD deal between Janssen and Cellular Biomedicine Group to develop next generation CAR T therapies signals a strong willingness to invest in the field. The deal raises commercial hopes for other players in the CAR T space. One of these is Elicera Therapeutics, whose candidate, ELC-301, also targets the CD20 antigen for the treatment of Non-Hodgkin's Lymphoma.

Read the article at biostock.se:

Janssen CAR T deal supports Elicera’s vision - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/